Precision Diagnosis and Treatment for Cancer

View Video

Introduction to Genecast

Founded in November, 2014, Genecast (Beijing) Biotechnology Co. is located in HealthWork (Beijing) Industry Park. With liquid biopsy, NGS and bioinformatics as our core technology, we are dedicated to improving cancer treatment through precision cancer diagnosis /companion diagnosis .

Genecast Biotechnology has established a technology platform for cell-free DNA NGS based test for companion diagnosis, genetic profiling, prognosis and monitoring for multiple solid tumors.(Lung cancer, colorectal cancer, liver cancer, esophageal cancer, endometrial cancer, ovarian cancer and cervical cancer).

Read More

Advanced In-house Technology Platform

  • Capture technology with the best uniformity

    Roche SeqCap

  • Detection of various types of mutations in SNV, in/del

    Copy number variation, gene rearrangement

  • High throughput sequencing platform

    Illumina HiSeq X Ten

Depth of Sequencing

Leader of cancer liquid biopsy

Capture Technology with the best uniformity

  • Product development support based on big data analysis

    Accumulated 10,000 sample tested with comprehensive treatment profile data to support future product development

  • Highly effective product development and translational research

    Developed 5~8 NGS panels for solid tumors within two years. Launched hundreds of clinical collaborationprojects for various solid tumors

  • Pioneer of liquid biopsy test in China

    Focus on cancer therapy. Pioneer of liquid biopsy test for tumor profiling , prognosis and monitoring throughout the entire treatment course

  • “Dream Team” covering all areas of expertise

    Top experts from the areas in medicine, biology, pharmacy, electronic technology, etc. Best sales and marketing team in the industry

Development History




“Angel Round” Financing of 2.5 million


1st Employee


Launch of BaishiboR


“A Round” Financing of 26 million RMB


Moved into HealthWork


 “B Round” Financing of 128 million RMB


Approved of Genecast (Wuxi) Precision Medicine Laboratory


 Inauguration of Genecast Lab (Phase II) 


Launch of PaidiwanTM


4 Papers at ASCO 2017


Passed NGS National Standard by National Institute for Food and Drug Control


Launch of LangshiboTM and ChangshiboTM


Accumulation of 20,000 test samples


Presented data in Lung Cancer Testing in WCLC 2017


Certificate of ddPCR Diagnosis Kits of Lung Cancer and CRC from National Institute for Food and Drug Control

Enterprise Qualification

Inspection Qualification

  • Two independent Medical Testing Laboratories
  • 1200m² laboratory meeting the standard of high throughput sequencing lab issued by National Health and Family Planning Commission of the People's Republic of China
  • Special Clinic for precision diagnosis and treatment for cancer. Big Data Center of precision diagnosis and treatment for cancer (under construction)
  • 1400m² GMP production base in Taizhou
  • Medical inspection and verification education and training practice base for Beijing Union Medical College and School of Medicine of Peking University

Enterprise Certificate

  • National High-tech Enterprise Certification

  • Zhongguancun High-tech Enterprise Certification

  • CAP Accreditation

  • NCCL EQA Certification

View Details


  • Introduction to Genecast

    Taking the next generation sequencing technique and bioinformatics as its core, the company is dedicated to noninvasive cancer precision diagnosis and treatment, and companion diagnosis, providing the patients with individualized healthy guidance.

Du Bo

Founder & Chief Executive Officer

Bo Du is the Founder and CEO of Genecast (Beijing) Biotechnology Co. He is also a member of the Biotech Diagnosis Branch of China Medicinal Biotech Association.

Bo Du studied biology at Peking University, and over the years since his graduation there, he has accumulated a wealth of experience in investment, pharmaceuticals, and second-generation sequencing. 

Zhang Henghui

Co-founder, Chief Medical Officer

Henghui Zhang, M.D., PhD, Co-founder and Chief Medical Officer of Genecast (Beijing) Biotechnology Co. 
Henghui Zhang has been engaged in clinical and translational work for more than 10 years. This has endowed him with immense experience in clinical oncology and scientific research. He has participated in and lead a number of fund projects, including the National Natural Science Foundation of China, the Natural Science Funds of Beijing Municipality and the Doctoral Fund of Ministry of Education of China, among others. Simultaneously, he was a major participant in the national Eleventh Five-Year and Twelfth Five-Year Science and Technology Development Plans, has won four national invention patents, and has published more than 50 SCI papers. On top of this, he took the lead role of responsibility in the patent transfer of a new drug for a cancer vaccine therapy (0.12 billion RMB).

Prior to co-founding Genecast, Henghui Zhang worked at Peking University People’s Hospital and Peking University Hepatology Institute, and was engaged in clinical and translational work for more than 10 years. In roles such as project leader and co-leader, he was involved in preclinical development and research work for a number of therapeutic cancer vaccines and molecular diagnostics projects. 

Henghui Zhang graduated from Peking University with a master’s degree in medicine, and a doctorate in immunology from Capital Medical University.

Ma Guosheng

Co-founder & Vice President

Guosheng Ma is the vice president of Genecast (Beijing) Biotechnology Co. Over many years he has worked for numerous well-known multinational pharmaceutical companies and private enterprises, including Bristol-Myers Squibb, Sanofi-Aventis, Merck Serono, and Baitai, serving as regional manager, regional director, national sales director, and deputy manager of marketing respectively.
Guosheng Ma has more than 20 years of experience in the marketing and management of oncology drugs. He has obtained an in-depth understanding of the domestic pharmaceutical environment as well as its industry trends, and has unique insights into oncology drug marketing. 

In 2006, Guosheng Ma built a team of professionals to lead the launch of the anti-EGFR monoclonal antibody, cetuximab, in China and, in 2009, achieved sales of nearly 500 million yuan.

In 2010, Guosheng Ma joined Baitai Bio to lead up its marketing and sales. He successfully reversed its unfavorable market situation and grew sales of Nimotuzumab, China’s first independent anti-EGFR drug, to reach 500 million yuan, surpassing the market share of the original brand-name product by a multinational company.

Guosheng Ma studied medicine at Capital Medical University, graduating in 1988, and continued working there as an instructor until 1997.

Yang Tao

Deputy General Manager

Tao Yang, deputy general manager of Genecast (Beijing) Biotechnology Co. 

Tao Yang has worked in the healthcare industry for more than a decade and has worked in marketing and management functions for well-known foreign and private pharmaceutical biotechnology companies, including Sino-Swiss joint venture Sino-Swed Pharmaceutical Co., Ltd., Sino-US joint venture Suzhou Lida Pharmaceutical Co., Ltd., Schering-Plough (China) Co., Ltd., Sino-American joint venture Shanghai Schering-Ploughs Pharmaceutical Co., Ltd., Beijing Zheng Qing Yuan Bio-Engineering Co., Ltd., and Nanjing Ai Qirui Molecular Biotechnology Co., Ltd.

Prior to this, Tao Yang worked for eight years at a clinical hospital as a physician, rising to the position of chief physician of internal medicine, and accumulating a wealth of experience in clinical medicine and medical management.

Tao Yang graduated in medicine from Nanjing Medical College.

Ji He

Chief Information Officer

Ji He is the chief information officer of Genecast Biotechnology Co., Ltd. He has worked in many leading international enterprises, including OmniSeq, BioReference Laboratories, Leidos and Samuel Roberts Noble Foundation, where he lead in roles such as VP of bioinformatics, bioinformatics director, bioinformatics manager and director of scientific computing.

Ji He has an enormous amount of experience working internationally. He has more than a decade of experience in bioscience, and has gained outstanding achievements in genomics, biomedicine, informatics and computing. At OmniSeq, he developed the US’s first NGS diagnostic panel for cancer immunotherapy to be approved by NYS CLEP. He has published more than 40 articles in renowned international academic periodicals, including both Nature Genetics and Blood, and been in charge of seven research projects funded, with a total value of over 15 million dollars, by the United States Federal Government or state government. 

Ji He has extensive experience in research and management in both biomedicine and informatics, and has achieved impressive results. Just some of these include:
? leading a bioinformatics study of CLIA- and CLEP-certified laboratories, infrastructure, software engineering and production IT support, which focused on NGS tumor molecular tests;
? unifying and optimizing multiple pilot computing infrastructure systems; 
? leading the end-to-end development of bioinformatics channels of new molecular diagnosis tests in the field of genetics and oncology; 
? adopting a 24/7 workflow process for CLIA- and CAP-certified laboratories; and
? assisting in the transformation and development of computing and information settings (including hardware, software and personnel allocation) from SNP array platforms to the next-generation sequencing platforms.

Ji He earned a master’s degree in information science and information management from Shanghai Jiaotong University, and a PhD in computer science from the National University of Singapore. 

Weizhi Chen

Chief Scientific Officer

Weizhi Chen is the chief scientific officer of Genecast Biotechnology Co., Ltd. She has worked in several well-known enterprises at home and abroad, including Simcere Diagnostics (Jiangsu), GENEWIZ and SinoGenoMax, holding positions such as VP of R&D, director of R&D and operations and chief technical officer.
Weizhi Chen has been engaged in pharmaceutical research and development for many years and has an impressive background in medicine and molecular biology research. During her more than 20 years of work in biotechnology R&D in both China and the US, she has focused on medical R&D, company management, project operations and talent cultivation.

While at Simcere Diagnostics Weizhi Chen was in charge of the planning and execution of research and development strategies for clinical diagnostics and companion diagnostics product lines. She advanced technology platforms and quality management systems and guided development activities. She also lead teams in the development of precision medical products and services in clinical fields such as oncology, cardiovascular disease, neurology, autoimmunity, and infectious diseases.

Weizhi Chen is highly knowledgeable in all aspects of genomics and specializes in NGS research and clinical applications. At GENEWIZ she lead the GENEWIZ China R&D teams to advance NGS-based applications in the field of genomics. She was also in charge of operations and business development of molecular genetics and NGS product lines, and lead the development and commercialization of the company’s proprietary genomics-based antibody platform.

In addition to the above, Weizhi Chen was in charge of company's reagent development. She established comprehensive experimental facilities for drug R&D, including protein expression and purification, high throughput screening, and extraction and purification of natural products and cell cultures; and provided technical guidance for drug R&D. She has made many great academic achievement, including, but not limited to, publishing a number of articles in esteemed international academic periodicals, such as the European Journal of Neuroscience, the Journal of Biological Chemistry, and the Journal of Neuroscience.

Weizhi Chen earned her Doctor of Medicine degree at Peking Union Medical College, completed postdoctoral research at Harvard Medical School, and worked as an instructor at the Children’s Hospital of Boston, Harvard Medical School.

Wang Haibo

Chief Technical Officer

Haibo Wang, chief technical officer of Genecast (Beijing) Biotechnology Co., has worked at New York University, the City University of New York, Hunter College, UT Southwestern Medical Center, and Cincinnati Children’s Hospital Medical Center.

Haibo Wang has worked in the fields of neurobiology, tumor signal pathways, and tumor molecular biology for more than ten years. He has extensive experience in cutting-edge basic medical research, and a profound understanding of related technologies and scientific research management. He has published nineteen SCI papers as well as a number of articles?—with an impact factor of over fifteen points—in numerous internationally renowned academic journals, such as Cell, Nature Medicine, and Neuron.

Wang Haibo earned his PhD from Peking University’s School of Life Sciences and is a gold medal winner of the Global Biological Olympiad.

Li Liang

Vice President of Clinical Operations

Li Liang is the VP of clinical operations at Genecast Biotechnology Co., Ltd. He has held positions at many of the world’s leading medical enterprises and academic institutions, including Cloud Health Genomics, BioReference Laboratories, and Rutgers University, working as chief research officer, director and professor respectively.
Li Liang has been board certified in clinical molecular genetics and clinical cytogenetics by the American Board of Medical Genetics and Genomics (ABMGG), and received licensure from the clinical lab directors in New York, California and New Jersey.

Li Liang has almost 20 years of international experience in genetics, medicine and biology, and is well-versed in international systems and rules regarding genetic testing. He has outstanding abilities in strategy and commercial analysis, and has published more than 20 professional papers in respected academic journals from around the world.

In BioReference Laboratories, Li Liang led a team of pathologists, genetic counselors, bioinformatics experts and laboratory technicians in providing clinical testing services for tens of thousands of patients with cancer and genetic diseases in 50 states across the US every year. He also reviewed, approved and signed off reports for patients tested via a solid tumor and myeloid malignancy next generation sequencing (NGS) panel. Additionally, he designed and oversaw the validation of new tests for clinical use, and wrote validation summaries of new tests for approval from New Jersey and New York.

In Rutgers University, Li Liang established a CLIA/CAP-certified highly automatic and informationized clinical genetic (including NGS) test laboratory, and, within just a few months, obtained operating licenses from New Jersey, New York and California. He led the team there to quickly develop multiple clinical test items of tumor NGS, analysis and interpretation, and provided doctors at Rutgers Cancer Institute of New Jersey with guidance in performing targeted precision therapy in cancer patients. Additionally, he led the team to provide genetic test services for major pharmaceutical companies in drug R&D and clinical trials, including Merck and GlaxoSmithKline plc, and consulted on and supervised genetic test services for BGI Genomics.

Li Liang earned his bachelor’s degree and master’s degree from Wuhan University’s College of Life Sciences before going on to complete his PhD at Indiana University.

Jerry Wang

Vice President of Business Development

Dr. Jerry Wang, Vice President of Business Development at Genecast Biotechnology Co., Ltd, is responsible for the company’s business development and international collaboration. Prior to joining Genecast, he was head of market development at Illumina Greater China. This latter role followed Dr. Wang time at the Illumina headquarters in San Diego, California, where he accumulated more than seven years of BD experience overseeing new technology licensing, M&A and collaborations.  

He is well versed in sequencing industry dynamics and deeply involved in the development and marketing of various major sequencing platforms and applications, including the HiSeq-X instrument ($1000 genome), single-cell sequencing, and liquid biopsy technology development.  

Dr. Wang has also worked for Baxter BioScience, where he was responsible for licensing, and M&A in the areas of large molecule drug development, bio-surgery and regenerative medicine.  

He graduated from the University of Science and Technology of China. He also holds a PhD from Washington University in St. Louis and an MBA from the University of Chicago. 

Yinhong Zhao

Deputy General Manager of Government Affairs

Yinhong Zhao is the Deputy General Manager of Genecast Biotechnology Co., Ltd. She is responsible for policy affairs, including relationship building with the government sector; providing management with policy information, such as relevant industrial regulations; and assisting the company in applications for relevant certification licensing.  

Prior to this, Yinhong Zhao worked at the national science and technology competencies department for over ten years and is highly knowledgeable regarding policy affairs. In her career, she has also worked at the China National Center for Biotechnology Development, where she was engaged in the management of multiple biomedical projects within national scientific and technological programs, including Program 863, Program 973, the National Science and Technology Support Program and the National Key R&D Plan. She has participated in research and planning for development strategies, as well as in the revision of administrative measures for science and technology plans within relevant fields.

Yinhong Zhao gained her PhD in science from the Peking University School of Life Sciences.

Yilong Chen

Vice President of Marketing

Yilong Chen is the VP of marketing at Genecast Biotechnology Co., Ltd. In the past he worked at Beijing Sixth Hospital as well as many leading multinational pharmaceutical enterprises and domestic listed companies, including Pfizer, Roche, Merck Serono, Celgene, and Yifan. Across this time, he has held positions such as senior product manager, marketing manager and marketing director.

He has over 20 years of experience in the pharmaceutical industry. In this time he has intensively investigated and explored the industry, and witnessed China’s own rise in it. He has advanced concepts and gained notable experience in marketing, planning, promotion and brand management. While working at Beijing Sixth Hospital, he developed outstanding clinical awareness and thinking.

Yilong Chen graduated from the Medical School of Nantong University, majoring in clinical medicine. He also earned a Master of Business Administration (BiMBA) from Peking University.

Bi Da

Marketing Director

Da Bi is the marketing director of Genecast (Beijing) Biotechnology Co. Over his career, he has worked as regional manager at many well-known multinational pharmaceutical companies and private enterprises, including Wyeth, Sanofi-Aventis, Taiho Pharma in Japan, Merck Serono, Roche, and Biotech. 

Having worked in the biopharmaceutical industry for more than 10 years, Da Bi has accumulated extensive professional experience in clinical drug monitoring and approval, new product launches, product promotion product sales. One of his many impressive achievements includes reaching annual sales of more than 80 million yuan for a single product. In addition, he also has noteworthy experience in team management and excels in team coordination.

In 2016, Da Bi joined Genecast (Beijing) Biotechnology Co., where he took on responsibility for the company’s product planning and marketing.

Da Bi graduated from the Chinese People’s Liberation Army Air Force Military Medical University (the Fourth Military Medical University) where he majored in pharmaceutical preparations.

Li Xiao

Financial Director

Before joining Genecast, Li Xiao has worked for several well-known companies, such as Watsons, Puhua Heshun's Beijing Fuerte Technology Co., Ltd., Lepus Medical's companies, serving as supervisor, financial controller, treasurer, and finance manager. 

Li Xiao has been engaged in financial work for more than 20 years, in industries such as FMCG, e-commerce, manufacturing, medical care, and biotechnology, which endows her comprehensive theoretical knowledge and financial management experience in finance and accounting.

In 2017, Li Xiao joined Genecast (Beijing) Biotechnology Co., in charge of the overall management of the company's financial management, corporate risk control, and procurement.

Li Xiao graduated from Beijing Institute of Technology with a major in accounting.

Suite 903-908, HealthWork, No. 35 Huayuan North Rd., Haidian District, Beijing

Follow WeChat public accounts and learn More

Copyright © 2014-2019 臻和(北京)科技有限公司 Genecast Biotechnology Co., Ltd. Design by Bobrand